

Discussion

Recent Advances in CRISPR-based Screening and Potential Applications

Yongcheng Jiang

Integrated Science Program, Yuanpei College



Outline of the discussion

- Recent advances and applications
- Limitations and future perspectives




What is the big picture of the field?

What technological/biological breakthroughs could it bring?

Recent advances and applications

How could traditional CRISPR screens be improved?


Traditional CRISPR screens pipeline



Targets: coding DNA only


Three main research frontiers

Library construction
and transfection




Cas9 CRISPR KO
dCas9 CRISPRi/a

Targeting non-
coding genome



Cas9 CRISPR KO
dCas9 CRISPRi/a
Cas13 CRISPRi


Three main research frontiers



Three main research frontiers


Readout phenotypes and genotypes

Sort cells expressing low and high protein X



Survival/dropout
FACS markers [1]
sgRNA abundance [2]


Single-cell functional genomics




Single-cell sequencing

- Transcriptomics
- Genetic interactions
- Epigenomics

Traditional CRISPR screens pipeline




Perturbation



Pooled screens

Readout phenotypes and genotypes



Survival/dropout
FACS markers [1]
sgRNA abundance [1, 2]

Targets: coding DNA only


Targeting non-coding genome

Non-coding genome regulates phenotypic profiles of living systems

A large proportion (>98%) of genome is consist of non-coding sequence.

Enhancer, silencer, lncRNA...

CRISPR KO (Cas9) on struc. non-coding loci
 CRISPRi (dCas9) on lncRNA loci
 CRISPRi (Cas13) on RNA transcript




Struc. = chromatin structure related

Targeting non-coding genome




Cas9-mediated knockout on noncoding loci in Hi-C hubs

Hi-C network analysis → KO live/dead screening → Hi-C/single cell transcriptomics




Targeting non-coding genome

Deletion of essential hubs can alter the global chromatin structure






Targeting non-coding genome

dCas9-mediated interference on lncRNA loci in human cells



Targeting non-coding genome


Cas13-mediated interference on coding and non-coding RNAs



KRAS: endogenous gene
PPIB: endogenous gene
MALAT: nuclear transcript


Traditional CRISPR screens pipeline

Library construction
and transfection




Cas9 CRISPR KO
dCas9 CRISPRi/a
Cas13 CRISPRi

Perturbation



Pooled screens

Readout phenotypes
and genotypes



Survival/dropout
FACS markers [1]
sgRNA abundance [1, 2]

Targets: coding DNA only

Pooled screens are limited to low-content readouts

Traditional pooled screens



No individual information (i.e., morphology, protein dynamics)

Arrayed screens

Microscopy plus markers or dyes

Optical pooled screens

FACS or *in situ* sequencing



Pooled screens are limited to low-content readouts

Traditional pooled screens

No individual information (i.e., morphology, protein dynamics)


Arrayed screens

Microscopy plus markers or dyes

Optical pooled screens

FACS or *in situ* sequencing

Optical enrichment with **PA-mCherry**



Pooled screens are limited to low-content readouts

Traditional pooled screens


1. Only population-level data
2. Spatial data is lost
3. Relied on sgRNA enrichment

Arrayed screens

Microscopy
plus markers
or dyes

Optical pooled screens




FACS or
in situ
sequencing



Altering screening modalities


Optical pooled screens apply *in situ* sequencing to readout spatio-temporal phenotypes

barcode 1 \Rightarrow CCAGTACGAATG barcode 2 \Rightarrow GACAAGTACACT



Altering screening modalities


Optical pooled screens in identifying genes for activation of NF-κB



Phenotype imaging and *in situ* barcode amplification (2 days) \longrightarrow *In situ* sequencing (3 days)


Gene perturbation and phenotype data for each cell

Cell	Gene	Stimulant	Translocation score
1	Gene A	IL-1 β	x_1
\vdots	\vdots	\vdots	\vdots
M	Gene Z	IL-1 β	x_M
<hr/>			
1	Gene A	TNF- α	x_1
\vdots	\vdots	\vdots	\vdots
N	Gene Z	TNF- α	x_N




Traditional CRISPR screens pipeline

Library construction
and transfection




Cas9 CRISPR KO
dCas9 CRISPRi/a
Cas13 CRISPRi

Perturbation



Pooled screens
Arrayed screens
OP. screens

Readout phenotypes
and genotypes




Survival/dropout
FACS markers [1]
sgRNA abundance [1, 2]

Targets: coding DNA only

Single-cell omics capture individual genomic profiles

1. Cells and enzymes are mixed with gel beads.
2. Lysis and RT happens in the GEM.



3. Library construction after breaking the emulsion.
4. NGS sequencing.


GEM = gel bead-in-emulsion

CBC = cell barcode

UMI = unique molecular identifier



GBC = guide barcode

Perturb-seq combines pooled CRISPR screens with scRNA-seq



$$Y = X\beta$$

Regularized linear model



$$\log(\text{Cells} + 1) = \text{Cells} \begin{bmatrix} 1 & 0 & 0 & \dots & -0.1 & \dots \\ 0 & 1 & 0 & \dots & 0.3 & \dots \\ 0 & 0 & 1 & \dots & 0.2 & \dots \\ \dots & \dots & \dots & \dots & \dots & \dots \\ 0 & 0 & 0 & \dots & -0.2 & \dots \end{bmatrix} \begin{bmatrix} \beta_{1,1} & \beta_{1,2} & \beta_{1,3} & \dots & \beta_{1,G} \\ \beta_{2,1} & \beta_{2,2} & \beta_{2,3} & \dots & \beta_{2,G} \\ \beta_{3,1} & \beta_{3,2} & \beta_{3,3} & \dots & \beta_{3,G} \\ \dots & \dots & \dots & \dots & \dots \\ \beta_{C,1} & \beta_{C,2} & \beta_{C,3} & \dots & \beta_{C,G} \end{bmatrix}$$

Expression matrix Design matrix Coefficient (regulatory) matrix


Genes Covariates Genes

Signature decomposition Cell features Inference

Design of experiments Interpretation

Single-cell functional genomics

Mapping genetic interactions with dual-gene perturbations



Workflows:


1. Library construction (2sgRNA/vec.)
2. Pooled screen
3. Readout cell proliferation
4. Calculate GI scores

222784 gene pairs in two cancer cell lines were perturbed.

1. Identify synthetic lethal interactions.
2. Assign gene function in clusters.


Single-cell functional genomics

Perturb-ATAC combines pooled CRISPR screens with chromatin accessibility profiling of single cells




Single-cell functional genomics


Perturb-ATAC CRISPRi screens in B lymphoblasts



ENH2 knockdown




EBER2 knockdown



X-axis: diff. in accessibility; Y-axis: false discovery rate

Perturbations of diverse categories of *trans*-factors alter corresponding epigenomic phenotypes

Advanced CRISPR screens pipeline



Targets: every parts of the genome!

(theoretically)

Limitations and future perspectives

What are the constraints of CRISPR screens?

Major caveats and challenges

Mutual problems

False data interpretation (i.e., ineffective guides, exon skipping, post-translational modification, off-target effect)

CRISPR KO

Impractical indel for non-coding sequence

CRISPRi/a

Low efficiency; 1kb-window around the TSS

GIs

Low throughput due to the exponential rule

Single-cell FG

Low throughput due to high cost in preparation


How to design better guide RNA library?

TSS = transcription start site;

sgRNA design tools make different tradeoffs

Features to consider

Species, Cas enzymes (PAM), on/off-target predictions...



CHOPCHOP

prioritizes multiple-hits transcripts

CRISPick

consider spacing requirements

GUIDES

prioritize annotated domains

The future of CRISPR functional genomic screening

- Better pilot studies and library design to narrow the experimental space.
- Integration with genomic database (i.e., GWAS) for complex cell models.
- Combination with single-cell multiomics (i.e., CITE-seq) more complex expression profiles.

Has there been a major breakthrough in our understanding of genomics that could not have been possible without CRISPR screens?

PNAS

Genome-wide CRISPR screen identifies transcriptional repressors of mitophagy

Christoph Potting^a, Christophe Crochet^a, Walter Carbone^a, Judith Knehr^a, Robert John S. Reece-Hoyes^b, Gregory R. Iversen^a and Stephen B. Helliwell^{a,1}



ARTICLE

Identification of immunomodulatory factors

LETTER

Shashank J. Patel^{1,2*}, Jared J. Gartner¹, Li Jia¹, Ophir Shalem⁶, Eric Topol³, Steve Feldman¹, Glenn

A CRISPR screen defines a pathway required by flaviviruses for replication

Rong Zhang¹, Jonathan J. Miner¹, Matthew J. Gorman¹, Keiko Rausch², Holly Ramage², James P. White¹, Adam Zuiani¹, Ping Zhang^{1,3}, Estefania Fernandez¹, Qiang Zhang¹, Kimberly A. Dowd⁴, Theodore C. Pierson⁴, Sara Cherry² & Michael S. Diamond^{1,5,6,7}

In vivo Perturb-Seq reveals neuronal and glial abnormalities associated with autism risk genes

Xin Jin^{1,2,3,4,*}, Sean K. Simmons^{3,5,6}, Amy Guo³, Ashwin S. Shetty², Michelle Ko², Lan Nguyen^{3,6}, Vahbiz Jokhi², Elise Robinson^{3,5,8}, Paul Oyler², Nathan Curry², Giulio Deangeli², Simona Lodato⁷, Joshua Z. Levin^{3,5,6}, Aviv Regev^{3,6,9,10,*†}, Feng Zhang^{3,4,10,*†}, Paola Arlotta^{2,3,5,*†}

CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity

Science

REPORTS

Cite as: S. Parvez *et al.*, *Science* 10.1126/science.abi8870 (2021).

MIC-Drop: A platform for large-scale in vivo CRISPR screens

Saba Parvez¹, Chelsea Herdman², Manu Beerens³, Korak Chakraborti¹, Zachary P. Harmer^{1†}, Jing-Ruey J. Yeh⁴, Calum A. MacRae³, H. Joseph Yost², Randall T. Peterson^{1*}

¹Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA. ²Department of Neurobiology and Molecular Medicine Program, University of Utah School of Medicine, Salt Lake City, UT, USA. ³Department of Cardiovascular Medicine, Genetics and Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁴Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

†Present address: Cellular and Molecular Biology, University of Wisconsin-Madison, Madison, WI, USA.

*Corresponding author. Email: randall.peterson@pharm.utah.edu


Citation analyses might give us some clues...

Presume that real-promising techniques should be adopted by other labs. We define citation ratio CR:

$$CR = \frac{\# \text{ of articles}}{\# \text{ of reviews}}$$

The bigger the CR, the more prevailing the novel technique is.

Simple pooled screens are the major screening method, while single-cell methods are emerging.



The fates of any new technologies

Novel techniques always undergo an evolution...

The initial, hyper-enthusiastic phase is often mixed with outrageous claims about the novel method's power and specificity.

In the maturational stage, the claimed super specificity and super sensitivity issues are reduced and replaced by more sober understanding of the objective and reliable values of the method.

In the third phase, the innovation is adopted by a large community and combined with other methods. This is typically the stage when major breakthroughs are expected.

CRISPR screening is currently in the _____ phase?

Take-home message

1. CRISPR screening is a programmable genome-wide high throughput method for genotype-phenotype mapping.
2. Its workflow could be tailored to different Cas enzymes, guide RNA libraries, screening formats, and readout methods.
3. Limitations in guide RNA library construction still exist, and traditional pooled screens are still the most common methods.

